Uncharted territory: challenges and opportunities in pediatric sleep medicine during the COVID-19 pandemic and beyond part I: clinical services and teaching and training issues.
Ontology highlight
ABSTRACT:
SUBMITTER: Owens J
PROVIDER: S-EPMC8214313 | biostudies-literature | 2021 Dec
REPOSITORIES: biostudies-literature
Publications
Uncharted territory: challenges and opportunities in pediatric sleep medicine during the COVID-19 pandemic and beyond part I: clinical services and teaching and training issues.
Owens Judith J Katwa Umakanth U Sheldon Stephen S Chen Maida M Zhou Eric E Hopkins Bobbi B Palomo Regina R Moore Maile M
Sleep medicine 20210619
Similar Datasets
Project description: Not available
| S-EPMC8215875 | biostudies-literature
Project description:Botulinum neurotoxins (BoNTs) produce local chemo-denervation by cleaving soluble N-ethylmaleimide-sensitive factor activating protein receptor (SNARE) proteins. Botulinum neurotoxins are therapeutically indicated in several neurological disorders and have been in use for three decades. The long-term efficacy, safety, and side effects of BoNTs have been well documented in the literature. However, the development of muscle atrophy following chronic exposure to BoNTs has not received sufficient attention. Muscle atrophy is not only cosmetically distressing, but also has an impact on future injections. An extensive literature search was conducted on atrophy and mechanisms of atrophy. Five hundred and four relevant articles in the English language were reviewed. This review revealed the surprising lack of documentation of atrophy within the literature. In addition, as demonstrated in this review, the mechanisms and the clinical factors that may lead to atrophy have also been poorly studied. However, even with this limited information it is possible to indicate factors that could modify the clinical approach to botulinum toxin injections. This review highlights the need for further study of atrophy following BoNT injections.
| S-EPMC6115806 | biostudies-literature
Project description:Infections continue to be a major cause of disease and contributor to death in patients on dialysis. Despite our knowledge and acceptance that hemodialysis catheters should be avoided and eliminated, most patients who begin dialysis initiate treatment through a central vein hemodialysis catheter. Dialysis Medical Directors must be the instrument through which our industry changes. We must lead the charge to educate our dialysis staff and our dialysis patients. We must also educate ourselves so that we not only know that our facility policies are consistent with the best evidence available, but we must also know where local and federal regulations differ. When these differences impact on patient care, we must speak out and have these regulations changed. But it is not enough to know the rules and write them. We must lead by example and show our patients, our nephrology colleagues and our dialysis staff that we always follow these same policies. We need to practice what we preach and be willing and available to redirect those individuals who have difficulty following the rules. In order to effectively change process meaningful data must be collected, analyzed and acted upon. Dialysis Medical Directors must direct and lead the quality improvement process. We hope this review provides Dialysis Medical Directors with the necessary tools to effectively drive this process and improve care.
| S-EPMC4422234 | biostudies-literature
Project description:Transthyretin amyloid cardiomyopathy (ATTR-AC) is an under-recognized and underdiagnosed disease. Although traditionally considered a rare condition, the epidemiology of the disease is rapidly changing due to the possibility of non-invasive diagnosis through cardiac scintigraphy with bone tracers and novel disease-modifying treatments providing survival advantages. Nevertheless, many questions and grey areas have to be addressed, such as the natural history of ATTR-AC, the role and implications of genotype-phenotype interactions, the best clinical management, prognostic stratification and the most appropriate treatments, including those already recommended for patients with heart failure. Clinicians have to cope with old beliefs and evolving concepts in ATTR-AC. A wide horizon of possibilities for physicians of many specialties is unfolding and awaits discovery.
| S-EPMC7534738 | biostudies-literature
Project description:The synthesis of polymer/oligomer-stabilized metal nanostructures (MNS) opens up a wide range of possibilities, from fundamental materials science to practical applications in domains such as medicine, catalysis, sensing, and energy. Because of the versatility of this synthetic approach, it is a dynamic and ever-changing field of study. These polymers/oligomers have precise control over the nucleation and growth kinetics, allowing the production of mono-disperse MNS with well-defined properties. The protective coating provided by polymers or oligomers increased the stability and colloidal dispersity of MNS in these oligomer-MNS composites. As a result, the current research reports the electrocatalytic reduction of nitrobenzene (NB) utilizing oligomeric aminomercaptotriazole (oligo AMTa) and oligo (AMTa-AuNS) modified glassy carbon (GC) electrodes developed via a wet chemical technique. UV-visible spectroscopy, Fourier-transform infrared spectroscopy (FT-IR), X-ray photoelectron spectroscopy (XPS), high resolution mass spectroscopy (HR-MS), and high-resolution transmission electron microscopy (HR-TEM) approaches were used to confirm the development of oligomer and AuNS. After that, the GC electrode was directly linked to the oligo AMTa and oligo AMTa-AuNS by dipping them in the appropriate solutions. Scanning electron microscopy (SEM), electrochemical impedance spectroscopy (EIS), and cycle voltammetry (CV) were all employed to confirm the fabrication of oligo AMTa and oligo AMTa-AuNS. Eventually, the electrochemical reduction of NB occurred using the fabricated electrodes. The catalytic activity of oligo AMTa-AuNS has been observed to be more than that of the other modified electrode. As an outcome, the film was employed to determine the sensitivity level of NB, and a limit of detection (LOD) of 2.8 nM was found. The straight-forward method's practical utility was proven by measuring NB in lake sample water.
| S-EPMC11664328 | biostudies-literature
Project description:Blood vessel development is one of the most prominent steps in regenerative medicine due to the restoration of blood flow to the ischemic tissues and providing the rapid vascularization in clinical-sized tissue-engineered grafts. However, currently tissue engineering technique is restricted because of the inadequate in vitro/in vivo tissue vascularization. Some challenges like as transportation in large scale, distribution of the nutrients and poor oxygen diffusion limit the progression of vessels in smaller than clinically relevant dimensions as well in vivo integration. In this regard, the scholars attempted to promote the vascularization process relied on the stem cells (SCs), growth factors as well as exosomes and interactions of biomaterials with all of them to enable the emergence of ideal microenvironment which is needed for treatment of unhealthy organs or tissue regeneration and formation of new blood vessels. Thus, in the present review we aim to describe these approaches, advances, obstacles and opportunities as well as their application in regeneration of heart as a prominent angiogenesis-dependent organ.
| S-EPMC7539317 | biostudies-literature
Project description:BackgroundBiobanks are highly organized infrastructures that allow the storage of human biological specimens associated with donors' personal and clinical data. These infrastructures play a key role in the development of translational medical research. In this context, we launched, in November 2015, the first biobank in Morocco (BRO Biobank) in order to promote biomedical research and provide opportunities to include Moroccan and North African ethnic groups in international biomedical studies. Here, we present the setup and the sample characteristics of BRO Biobank.MethodsPatients were recruited at several departments of two major health-care centers in the city of Oujda. Healthy donors were enrolled during blood donation campaigns all over Eastern Morocco. From each participant, personal, clinical, and biomedical data were collected, and several biospecimens were stored. Standard operating procedures have been established in accordance with international guidelines on human biobanks.ResultsBetween November 2015 and July 2020, 2446 participants were recruited into the BRO Biobank, of whom 2013 were healthy donors, and 433 were patients. For healthy donors, the median age was 35 years with a range between 18 and 65 years and the consanguinity rate was 28.96%. For patients, the median age was 11 years with a range between 1 day and 83 years. Among these patients, 55% had rare diseases (hemoglobinopathies, intellectual disabilities, disorders of sex differentiation, myopathies, etc.), 13% had lung cancer, 4% suffered from hematological neoplasms, 3% were from the kidney transplantation project, and 25% had unknown diagnoses. The BRO Biobank has collected 5092 biospecimens, including blood, white blood cells, plasma, serum, urine, frozen tissue, FFPE tissue, and nucleic acids. A sample quality control has been implemented and suggested that samples of the BRO Biobank are of high quality and therefore suitable for high-throughput nucleic acid analysis.ConclusionsThe BRO Biobank is the largest sample collection in Morocco, and it is ready to provide samples to national and international research projects. Therefore, the BRO Biobank is a valuable resource for advancing translational medical research.
| S-EPMC7738781 | biostudies-literature
Project description: Not available
| S-EPMC9359957 | biostudies-literature
Project description:Background:Clinical pharmacy is a branch of health sciences that focuses more on the patient than on drug product-oriented services to optimize drug therapy. This study aimed to assess attitudes, opportunities, and challenges for clinical pharmacy services from the health care providers' perspective in Mizan-Tepi University Teaching Hospital. Methods:A cross-sectional study was conducted among physicians, nurses, pharmacy professionals, and public health officers working in Mizan-Tepi University Teaching Hospital. A total of 119 health care providers participated in the study, and data were collected using a pretested self-administered questionnaire. The study tool was designed based on the instruments used in the previously conducted studies. Collected data were coded, entered, and analyzed using Statistical Package for the Social Sciences (SPSS, version 21). Furthermore, the descriptive and inferential statistics were performed. Results:Out of 119 health care providers included in the study, 59.66% of them were nurses. The majority of the health care providers (85.71%) had a positive attitude towards clinical pharmacy services. Most of the study participants mentioned that acceptance of clinical pharmacy services among health care providers as a major opportunity to clinical pharmacy services in Mizan-Tepi University Teaching Hospital. The major challenges described for the clinical pharmacy services include lack of support from hospital management, absence of clearly defined roles and responsibilities for the clinical pharmacists, and shortage of pharmacy workforce and staff turnover. Conclusion:Proper strategies should be in place to improve clinical pharmacy services and promote pharmacists' role in providing patient care.
| S-EPMC7150678 | biostudies-literature
Project description: Not available
| S-EPMC7077926 | biostudies-literature